Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Since the first solid organ transplant between the Herrick twins in 1954, transplantation immunology has sought to move away from harmful immunosuppressive regimens towards tolerogenic strategies that promote long-term graft survival. This has required a concerted multinational effort with scientists and clinicians working towards a common goal. Reports of immunosuppression-free kidney and liver allograft recipients have provided the proof-of-principle, but intentional generation of tolerance in clinical transplantation is still only achieved infrequently. Recently, there have been an increasing number of encouraging developments in the field in both experimental and clinical studies. In this article, we review the latest advances in tolerance research and consider possible future barriers and solutions in achieving reliable graft acceptance in the long term.

Original publication

DOI

10.1111/tri.12081

Type

Journal article

Journal

Transpl Int

Publication Date

06/2013

Volume

26

Pages

576 - 589

Keywords

Biomarkers, Bone Marrow Transplantation, Calcineurin Inhibitors, Graft Survival, Humans, Immune Tolerance, Immunosuppression, Kidney Transplantation, Liver Transplantation, Transplantation Immunology, Transplantation Tolerance